Focus: Armata Pharmaceuticals is a public biotech company developing natural and synthetic bacteriophage-based therapies targeting bacterial infections and related conditions. The company operates at a pre-revenue stage with a focused pipeline in early-to-mid clinical development.
Profile data last refreshed 9m ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Armata Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Armata Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Armata Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) The Globe and Mail
Why Is Armata Pharma Stock Gaining Monday? - Benzinga
Why Is Armata Pharma Stock Gaining Monday? Benzinga
Armata Pharmaceuticals Granted FDA Fast Track Designation for AP-SA02 - HarianBasis.co
Armata Pharmaceuticals Granted FDA Fast Track Designation for AP-SA02 HarianBasis.co
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP Moomoo
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update PR Newswire
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - PR Newswire
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 PR Newswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo